Carfilzomib

규격

868540-17-4CAS 번호

692-054-2EC 번호

(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamideIUPAC 명칭

C40H57N5O7화학식

719.9 g/mol분자량

Carfilzomib; 868540-17-4; Kyprolis; PR-171; DTXSID4048690; NSC-758252; 72X6E3J5AR; DTXCID0028616; CHEBI:65347; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide; L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-; carfilzomibum; PR171; (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide; N-((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-L-phenylalaninamide; RefChem:57059; L01XX45; Carfilzomib (PR-171); Carfilzomib (PR171); MFCD11040997; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; C40H57N5O7; CHEMBL451887; (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide; NCGC00249613-01; UNII-72X6E3J5AR; Carfilzomib [USAN]; CAS-868540-17-4; (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib [USAN:INN]; Kyprolis (TN); Carfilzomib; PR171; Carfilzomib (Standard); CARFILZOMIB [MI]; CARFILZOMIB [INN]; CARFILZOMIB [JAN]; CARFILZOMIB [VANDF]; Carfilzomib (PR-171)?; SCHEMBL85165; CARFILZOMIB [WHO-DD]; MLS006011102; Carfilzomib (JAN/USAN/INN); GTPL7420; orb1307429; CARFILZOMIB [ORANGE BOOK]; BLMPQMFVWMYDKT-NZTKNTHTSA-N; GLXC-90068; EX-A2037; ONO-7057; Tox21_113079; BDBM50277889; EBC-17178; HY-10455R; NSC756640; NSC758252; s2853; AKOS025401910; Tox21_113079_1; CCG-270405; CS-0984; CS-W004540; DB08889; FC46443; NSC 758252; NSC-756640; NCGC00249613-02; NCGC00249613-03; NCGC00249613-08; NCGC00249613-11; NCGC00249613-13; (2S)-N-[(1S)-1-benzyl-2-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]amino]-2-oxo-ethyl]-4-methyl-2-[[(2S)-2-[(2-morpholinoacetyl)amino]-4-phenyl-butanoyl]amino]pentanamide; (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide; AC-27051; AS-17059; BP-43632; HY-10455; SMR004660024; SY068813; NS00072616; SW218090-2; D08880; AB01565867_02; F951459; SR-01000941582; SR-01000941582-1; BRD-K15179879-001-03-2; Q15366934; (|AS)-|A-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; (aS)-a-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalani namide; (S)-4-Methyl-N-[(S)-1-[[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxo-2-pentyl]amino]-1-oxo-3-phenyl-2-propyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]pentanamide; L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-; N-{(2S)-2-[2-(Morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide동의어